GEP20196989B - Pharmaceutical composition comprising bisoprolol and perindoril - Google Patents

Pharmaceutical composition comprising bisoprolol and perindoril

Info

Publication number
GEP20196989B
GEP20196989B GEAP201514507A GEAP2015014507A GEP20196989B GE P20196989 B GEP20196989 B GE P20196989B GE AP201514507 A GEAP201514507 A GE AP201514507A GE AP2015014507 A GEAP2015014507 A GE AP2015014507A GE P20196989 B GEP20196989 B GE P20196989B
Authority
GE
Georgia
Prior art keywords
bisoprolol
perindoril
pharmaceutical composition
perindopril
filler
Prior art date
Application number
GEAP201514507A
Inventor
Laboratoires Servier Les
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20196989(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of GEP20196989B publication Critical patent/GEP20196989B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition contains bisoprolol, perindopril and a filler; at that, bisoprolol and perindopril are physically separated.
GEAP201514507A 2014-11-05 2015-11-04 Pharmaceutical composition comprising bisoprolol and perindoril GEP20196989B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (en) 2014-11-05 2014-11-05 PHARMACEUTICAL COMPOSITION COMPRISING A BETABLOQUANT AND A CONVERSION ENZYME INHIBITOR

Publications (1)

Publication Number Publication Date
GEP20196989B true GEP20196989B (en) 2019-07-10

Family

ID=52345359

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201514507A GEP20196989B (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising bisoprolol and perindoril

Country Status (24)

Country Link
EP (1) EP3215130B1 (en)
CY (1) CY1123322T1 (en)
DK (1) DK3215130T3 (en)
EA (1) EA032808B1 (en)
ES (1) ES2811904T3 (en)
FR (1) FR3027803B1 (en)
GE (1) GEP20196989B (en)
HR (1) HRP20201518T1 (en)
HU (1) HUE051947T2 (en)
LT (1) LT3215130T (en)
MA (1) MA40915B1 (en)
MX (1) MX372717B (en)
MY (1) MY187357A (en)
PH (1) PH12017500786B1 (en)
PL (1) PL3215130T3 (en)
PT (1) PT3215130T (en)
RS (1) RS60657B1 (en)
RU (1) RU2702362C2 (en)
SG (2) SG10201903656RA (en)
SI (1) SI3215130T1 (en)
TN (1) TN2017000170A1 (en)
UA (1) UA122131C2 (en)
WO (1) WO2016071631A1 (en)
ZA (1) ZA201703078B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118076591A (en) 2021-10-20 2024-05-24 法国施维雅药厂 Novel trimetazidine salts
WO2024218267A2 (en) 2023-04-20 2024-10-24 Les Laboratoires Servier Novel trimetazidine solid phases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040137054A1 (en) 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable combination medicine
NZ596064A (en) * 2009-04-30 2014-03-28 Reddy’S Lab Ltd Dr Fixed dose drug combination formulations
SI2857014T1 (en) 2010-05-06 2016-09-30 Cal International Limited A pharmaceutical composition comprising aspirin and bisoprolol

Also Published As

Publication number Publication date
RU2702362C2 (en) 2019-10-08
PH12017500786A1 (en) 2017-10-02
SI3215130T1 (en) 2020-11-30
FR3027803A1 (en) 2016-05-06
PL3215130T3 (en) 2020-11-16
LT3215130T (en) 2020-08-25
MX2017005848A (en) 2017-06-27
TN2017000170A1 (en) 2018-10-19
MY187357A (en) 2021-09-22
RU2017115341A3 (en) 2019-05-21
CY1123322T1 (en) 2021-12-31
PT3215130T (en) 2020-08-26
PH12017500786B1 (en) 2023-10-11
SG11201703550SA (en) 2017-06-29
FR3027803B1 (en) 2018-02-09
EA032808B1 (en) 2019-07-31
EP3215130B1 (en) 2020-07-08
MA40915B1 (en) 2020-08-31
HUE051947T2 (en) 2021-03-29
ES2811904T3 (en) 2021-03-15
UA122131C2 (en) 2020-09-25
ZA201703078B (en) 2020-11-25
WO2016071631A1 (en) 2016-05-12
EP3215130A1 (en) 2017-09-13
MX372717B (en) 2020-05-26
RU2017115341A (en) 2018-11-05
HRP20201518T1 (en) 2020-12-11
EA201790772A1 (en) 2017-09-29
SG10201903656RA (en) 2019-05-30
RS60657B1 (en) 2020-09-30
DK3215130T3 (en) 2020-09-21

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical compositions and uses thereof
EP3237051A4 (en) Gender based full - face mask sizes
EP3223920A4 (en) Water-enhancing, fire-suppressing hydrogels
EP3228662A4 (en) Composition for gel cushion, and gel cushion manufactured therefrom
GB201408673D0 (en) Medicaments,uses and methods
PL3223796T3 (en) Pharmaceutical compositions, preparation and uses thereof
EP3150212A4 (en) Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same
IL252897A0 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
HUE067642T2 (en) Pharmaceutical composition, preparation and uses thereof
IL252397A0 (en) Pharmaceutical composition, preparation and uses thereof
EP3141243A4 (en) Pharmaceutical composition
SI3220893T1 (en) Composition based on coq10
EP3190129A4 (en) Centrally-acting peptide derivative, and pharmaceutical composition
EP3197488A4 (en) Compositions comprising ch505 envelopes, and trimers
IL276030A (en) All natural, non-toxic sublingual drug delivery systems
GEP20196989B (en) Pharmaceutical composition comprising bisoprolol and perindoril
EP3170512A4 (en) Pharmaceutical composition
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
EP3534897A4 (en) Novel dosage regimen
ZA201701714B (en) Anthostema senegalense-based composition, for use as an anti-aids drug
HK40112156A (en) Medicaments, uses and methods
HK40115817A (en) Pharmaceutical composition, preparation and uses thereof
HK40012526A (en) Novel dosage regimen
IN2013MU03310A (en)
UA99992U (en) 2,34-tetrahydropyridin-6-thiolate